Plitidepsin
Sponsors
Fundacion Fls De Lucha Contra El Sida Las Enfermedades Infecciosas Y La Promocion De La Salud Y La C, PharmaMar, Institut Bergonié
Conditions
Adult Patients With Unresectable Locally Advanced or Metastatic, Relapsed/Refractory Dedifferentiated LiposarcomaCOVID-19COVID-19 InfectionLymphomaMultiple MyelomaRelapsed/Refractory Multiple Myelomapost-COVID-19 Condition (PCC)
Phase 1
Phase 2
A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma
CompletedNCT00229203
Start: 2005-02-28End: 2008-08-31Updated: 2009-12-24
Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial
TerminatedNCT01876043
Start: 2012-02-29End: 2015-04-30Updated: 2021-01-25
A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma
TerminatedNCT03070964
Start: 2016-10-25End: 2018-07-31Updated: 2020-10-14
Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide
TerminatedNCT03117361
Start: 2017-05-08End: 2018-07-30Updated: 2020-12-02
Plitidepsin Versus Control in Immunocompromised Adult Participants With Symptomatic COVID-19 Requiring Hospital Care (NEREIDA)
TerminatedNCT05705167
Start: 2023-04-19End: 2024-04-19Updated: 2024-12-02
Phase II proof-of-concept, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of plitidepsin in adults with post-COVID-19 Condition (PCC)
RecruitingCTIS2024-516378-31-00
Start: 2025-02-07Target: 90Updated: 2025-07-31
Phase 3
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
CompletedNCT01102426
Start: 2010-06-30End: 2017-11-30Updated: 2020-11-10
Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection
TerminatedNCT04784559
Start: 2021-06-04End: 2023-03-01Updated: 2025-02-21